Metoprolol succinate
Pro Research Analysisby 
Searched over 200M research papers for "metoprolol succinate"
Metoprolol Succinate: Drug Class, Mechanism, and Formulation
Metoprolol succinate is a beta1-selective (cardioselective) adrenoceptor blocking agent, commonly known as a beta-blocker. It is formulated as an extended-release tablet designed to provide a controlled and predictable release of the drug for once-daily administration. The extended-release tablets contain multiple controlled-release pellets, each acting as a separate drug delivery unit to ensure continuous delivery over the dosage interval. Available strengths include 23.75, 47.5, 95, and 190 mg, equivalent to 25, 50, 100, and 200 mg of metoprolol tartrate, respectively .
Clinical Indications and Therapeutic Uses
Metoprolol succinate is indicated for several cardiovascular conditions:
- Hypertension: It lowers blood pressure, reducing the risk of fatal and non-fatal cardiovascular events, such as strokes and myocardial infarctions.
- Angina Pectoris: It is used to manage chest pain due to heart disease.
- Heart Failure: Specifically, it is indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin 27.
Efficacy in Heart Failure and Arrhythmias
Clinical studies have shown that metoprolol succinate is safe and well-tolerated in patients with heart failure. It is associated with an increase in left ventricular ejection fraction and a reduction in ventricular ectopic beats, indicating improved heart function and reduced arrhythmia risk . Systematic reviews confirm that metoprolol succinate provides significant mortality and morbidity benefits in heart failure and can reduce new incidents of atrial fibrillation in high-risk patients 67.
Formulation and Release Characteristics
Metoprolol succinate is available in sustained-release and extended-release formulations. These tablets are developed using various polymers to ensure a gradual release of the drug, matching USP specifications for dissolution over 20 hours. The half-life of metoprolol succinate is about 4-6 hours, but the extended-release formulation allows for once-daily dosing 49. Natural polymers like gums and mucilages are also being explored for their advantages in sustained-release formulations, such as being non-toxic, biodegradable, and cost-effective .
Polymorphism and Dissolution
A new polymorphic form of metoprolol succinate (Form II) has been identified, which has a lower melting temperature and dissolves more quickly in water compared to the previously known Form I. Form II is metastable and can convert to Form I under high temperature and humidity, but its better solubility may offer advantages in certain formulations .
Analytical Methods and Combination Formulations
Chemometric spectrophotometric methods have been developed for the simultaneous estimation of metoprolol succinate and amlodipine besylate in combined tablet formulations. These methods are accurate, validated, and suitable for quality control in pharmaceutical manufacturing .
Novel Delivery Systems
Fast-dissolving oral films of metoprolol succinate have been developed using solvent casting techniques. These films dissolve quickly in the mouth, providing rapid drug release and effective taste masking, which may improve patient compliance, especially in those who have difficulty swallowing tablets .
Conclusion
Metoprolol succinate is a well-established, cardioselective beta-blocker with proven benefits in hypertension, angina, heart failure, and arrhythmia management. Its extended-release formulation ensures consistent therapeutic levels with once-daily dosing. Ongoing research into new polymorphic forms, natural polymers for sustained release, and innovative delivery systems like fast-dissolving films continues to enhance its clinical utility and patient acceptability 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic